TY - JOUR
T1 - Immunogenicity and protective efficacy of recombinant Campylobacter jejuni flagellum-secreted proteins in mice
AU - Baqar, Shahida
AU - Applebee, Lisa A.
AU - Gilliland, Theron C.
AU - Lee, Lanfong H.
AU - Porter, Chad K.
AU - Guerry, Patricia
PY - 2008/7
Y1 - 2008/7
N2 - Immunogenicity and protective efficacy of three Campylobacter jejuni flagellum-secreted proteins, FlaC, FspA1, and FspA2, were compared by use of a mouse model. Mice were immunized intranasaily with each protein with or without LTR192G as the adjuvant and challenged intranasaily with C. jejuni 81-176 or CG8486. All three proteins were immunogenic, although FspA1 induced the highest levels of serum immunoglobulin G (IgG) and fecal IgA. Although immunogenic, FlaC provided only 18% protection against disease from C. jejuni 81-176. Immunization with FspA1 resulted in 57.8% protection without adjuvant or 63.8% protection with adjuvant against homologous challenge with 81-176. Alternatively, immunization with FspA2 provided 38.4% (without adjuvant) or 47.2% (with adjuvant) protection against disease from homologous challenge with CG8486. In contrast to FspA2, FspA1 provided some heterologous protection against C. jejuni CG8486 when delivered with (31.2%) or without (44.8%) LTR192G. These results suggest that FspA1 may be a good subunit vaccine candidate against C. jejuni disease.
AB - Immunogenicity and protective efficacy of three Campylobacter jejuni flagellum-secreted proteins, FlaC, FspA1, and FspA2, were compared by use of a mouse model. Mice were immunized intranasaily with each protein with or without LTR192G as the adjuvant and challenged intranasaily with C. jejuni 81-176 or CG8486. All three proteins were immunogenic, although FspA1 induced the highest levels of serum immunoglobulin G (IgG) and fecal IgA. Although immunogenic, FlaC provided only 18% protection against disease from C. jejuni 81-176. Immunization with FspA1 resulted in 57.8% protection without adjuvant or 63.8% protection with adjuvant against homologous challenge with 81-176. Alternatively, immunization with FspA2 provided 38.4% (without adjuvant) or 47.2% (with adjuvant) protection against disease from homologous challenge with CG8486. In contrast to FspA2, FspA1 provided some heterologous protection against C. jejuni CG8486 when delivered with (31.2%) or without (44.8%) LTR192G. These results suggest that FspA1 may be a good subunit vaccine candidate against C. jejuni disease.
UR - http://www.scopus.com/inward/record.url?scp=46449123459&partnerID=8YFLogxK
U2 - 10.1128/IAI.00076-08
DO - 10.1128/IAI.00076-08
M3 - Article
C2 - 18426878
AN - SCOPUS:46449123459
SN - 0019-9567
VL - 76
SP - 3170
EP - 3175
JO - Infection and Immunity
JF - Infection and Immunity
IS - 7
ER -